Hypertension Journal

1.GUEST EDITORIAL

Introduction

Sudarshan Ballal

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:125-126] [No. of Hits: 515]


ABSTRACT

Hypertension (HTN) is the most common risk factor for cardiovascular, cerebrovascular, and chronic kidney disease (CKD) affecting nearly two-thirds of adults aged 60 years or older. It is estimated that uncontrolled HTN is responsible for 7.5 million deaths/year worldwide and accounts for over 47 billion dollars spent for health care in the United States.

Received: 7-04-2018;

Accepted: 29-05-2018


2.REVIEW ARTICLE

New Guidelines for the Treatment of Hypertension: Re-emergence of Chlorthalidone in the Treatment of Hypertension

Ravi Jangamani, Sankaran Sundar

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:127-131] [No. of Hits: 541]


ABSTRACT

Hypertension is the most common modifiable risk factor for cardiovascular diseases, stroke, and renal dysfunction. Its treatment is the main focus of primary and secondary disease prevention strategies. The guidelines for the treatment of hypertension continues to evolve over the past few decades for early detection, risk stratification, and better control to improve clinical outcomes. This article highlights the newer guidelines for the treatment of hypertension and the role of diuretics.

Key words: Cardiovascular diseases, hypertension, renal dysfunction, stroke

How to cite this article: Jangamani R, Sundar S. New Guidelines for the Treatment of Hypertension: Re-emergence of Chlorthalidone in the Treatment of Hypertension. Hypertens 2018;4(3):127-131.

Source of support: Nil, Conflict of interest: None

Received: 12-04-2018;

Accepted: 03-06-2018


How to cite this article: Jangamani R, Sundar S. New Guidelines for the Treatment of Hypertension: Re-emergence of Chlorthalidone in the Treatment of Hypertension. Hypertens 2018;4(3):127-131.

Source of support: Nil, Conflict of interest: None

3.REVIEW ARTICLE

Endothelial Dysfunction and Hypertension

Sanjiv Rao, K. N. Manohar

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:132-134] [No. of Hits: 544] [No. of Citation: 1]


ABSTRACT

The endothelium the largest organ in the human body is no longer considered a dormant organ but is actively involved in the pathogenesis of hypertension. Its dysfunction brought about by various factors causes alteration in the vascular tone primarily and changes in the synthesis of various vasoactive substances which in turn contribute to the development of hypertension. Certain non pharmacological and pharmacological interventions aid in the improvement of the endothelial dysfunction.

Key words: Endothelial dysfunction, micro and macrovascular effects, vasoactive substances, hypertension

How to cite this article: Rao S, Manohar KN. Endothelial Dysfunction and Hypertension. Hypertens 2018;4(3): 132-134.

Source of support: Nil,

Conflict of interest: None

Received: 06-07-2018;

Accepted: 11-08-2018


How to cite this article: Rao S, Manohar KN. Endothelial Dysfunction and Hypertension. Hypertens 2018;4(3): 132-134.

Source of support: Nil,

Conflict of interest: None

4.REVIEW ARTICLE

Hypertension and Cardiac Arrhythmias

G. Sridhara

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:135-137] [No. of Hits: 448]


ABSTRACT

Hypertension is a major modifiable risk factor for atherosclerotic cardiovascular disease. Cardiac arrhythmias and conduction defects associated with hypertension could be the cause for serious morbidity and mortality. Hypertension leading to myocardial changes and drug induced dyselectrolemia are some of the factors in t he genesis of cardiac arrhythmias. Effective blood pressure control reduces the risk of arrhythmias.

Key words: Hypertension, Cardiac arryhtmia, Antihypertensive drugs

How to cite this article: Sridhara G. Hypertension and Cardiac Arrhythmias. Hypertens 2018;4(3):135-137.

Source of support: Nil,

Conflict of interest: None

Received: 4-04-2018;

Accepted: 16-6-2018


How to cite this article: Sridhara G. Hypertension and Cardiac Arrhythmias. Hypertens 2018;4(3):135-137.

Source of support: Nil,

Conflict of interest: None

5.REVIEW ARTICLE

Hypertension in Aging Population

Roopa Ravi Babu

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:138-142] [No. of Hits: 681]


ABSTRACT

Hypertension is a major problem among the geriatric population and is usually associated with multiple comorbidities and organ system damage. Isolated systolic hypertension is commonly found in older (60.79 years of age) and elderly (.80 years of age) people. It is now clear that isolated systolic hypertension and elevated pulse pressure also play an important role in the development of cerebrovascular disease, congestive heart failure, and coronary heart disease, which are the major causes of cardiovascular (CV) morbidity and mortality in the population aged older than 65 years. The elderly population represents several medical challenges, particularly in the management of hypertension. These individuals have more organ damage or clinical CV disease, and they may respond differently to treatment goals of normal aged populations. Each patient responds differently to treatment; thus, there is a need to individualize hypertension management in the elderly population.

Key words: Aging population, hypertension, systolic hypertension

How to cite this article: Babu RR. Hypertension in Aging Population. Hypertens 2018;4(3):138-142.

Source of support: Nil,

Conflict of interest: None

Received: 07-04-2018;

Accepted: 15-05-2018


How to cite this article: Babu RR. Hypertension in Aging Population. Hypertens 2018;4(3):138-142.

Source of support: Nil,

Conflict of interest: None

6.REVIEW ARTICLE

Hypertension in Pregnancy

B. S. Chakrapani

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:143-148] [No. of Hits: 760]


ABSTRACT

Hypertension disorders of pregnancy are the second most frequent cause of pregnancy associated maternal mortality. Accurate measurement of blood pressure is most essential and integral part of diagnosing Hypertensive Disorders of Pregnancy. Several risk factors for Pre-Eclampsia have been identified. Biomarkers are available for early detection of Pre-Eclampsia. There is growing awareness about Pre-Eclampsia as a risk factor for mother and fetus for future development of cardiovascular disease. This review covers most of the issues related to hypertension in pregnancy.

Key words: HDP-Hypertensive disorders of pregnancy, PHTN-Pregnancy related hypertension, CHTN-Chronic hypertension, PE-Pre eclampsia, SUASpiral uterine arteries

How to cite this article: Chakrapani BS. Hypertension in Pregnancy. Hypertens 2018;4(3): 143-148.

Source of support: Nil,

Conflict of interest: None

Received: 19-03-2018;

Accepted: 24-4-2018


How to cite this article: Chakrapani BS. Hypertension in Pregnancy. Hypertens 2018;4(3): 143-148.

Source of support: Nil,

Conflict of interest: None

7.REVIEW ARTICLE

Renal Sympathetic Denervation Therapy in Hypertension

V. Subash Chandra, N. Saleha

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:149-153] [No. of Hits: 504]


ABSTRACT

Sympathetic nervous system plays an important role in the pathogenesis of hypertension. In resistant hypertension, when pharmacotherpy fails, there may be a place for renal sympathetic denervation. Though initial studies showed promising results, sham controlled studies proved negative. However, learning lessons from the previous trials, recent studies probably with better design and methodology seem to be resurrecting renal sympathetic denervation therapy for resistant hypertension

Key words: Resistant hypertension, Sympathetic nervous system, Renal sympathetic denervation

How to cite this article: Chandra VS, Saleha N. Renal Sympathetic Denervation Therapy in Hypertension. Hypertens 2018;4(3):149-153.

Source of support: Nil,

Conflict of interest: None

Received: 18-02-2018;

Accepted: 19-03-2018


How to cite this article: Chandra VS, Saleha N. Renal Sympathetic Denervation Therapy in Hypertension. Hypertens 2018;4(3):149-153.

Source of support: Nil,

Conflict of interest: None

8.REVIEW ARTICLE

Hypertension and Cognitive Function

Uday Murgod

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:154-156] [No. of Hits: 530]


ABSTRACT

Persistent hypertension is a modifiable risk factor for stroke, cognitive impairment, and dementia. Cognitive impairment and dementia may be due to acute or recurrent strokes secondary to hypertension or due to chronic structural changes in the brain induced by chronic hypertension.

Key words: Hypertension, cognitive, dementia.

How to cite this article: Murgod U. Hypertension and Cognitive Function. Hypertens 2018;4(3):154-156.

Source of support: Nil,

Conflict of interest: None

Received: 19-05-2018;

Accepted: 19-06-2018


How to cite this article: Murgod U. Hypertension and Cognitive Function. Hypertens 2018;4(3):154-156.

Source of support: Nil,

Conflict of interest: None

9.REVIEW ARTICLE

Renin-angiotensin-aldosterone System Blockers, Hypertension, and Clinical Outcomes

S. Kishore Babu, Rohan Augustine

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:157-165] [No. of Hits: 760]


ABSTRACT

The renin-angiotensin-aldosterone system (RAAS) plays a key role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN). Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will refresh our current understanding of the RAAS pathway, examine anti-hypertensive medications affecting the RAAS, evaluate recent studies that help provide a better understanding of RAAS blockade on clinical outcomes and review newer RAAS blocking agents and RAAS modulation in clinical practice.

Key words: Advances, hypertension, outcomes, RAAS system, RAAS blockers

How to cite this article: Babu SK, Rohan A. Reninangiotensin-aldosterone System Blockers, Hypertension, and Clinical Outcomes. Hypertens 2018;4(3):157-165.

Source of support: Nil,

Conflict of interest: None

Received: 09-04-2018;

Accepted: 19-05-2018


How to cite this article: Babu SK, Rohan A. Reninangiotensin-aldosterone System Blockers, Hypertension, and Clinical Outcomes. Hypertens 2018;4(3):157-165.

Source of support: Nil,

Conflict of interest: None

10.REVIEW ARTICLE

Pathophysiology of Hypertension in Chronic Kidney Disease

Rashmi Srinivas, S. Vishwanath

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:166-169] [No. of Hits: 901]


ABSTRACT

There are a multitude of mechanism of pathogenesis of hypertension in CKD. The most important is the rennin angiotensin axis and the renal autoregulation. However the role of other mechanism like the sympathetic nervous system overactivity, drugs, endothelial dysfunction, genetics and oxidative stress cannot be ignored. In this article, we present a detailed description of the various mechanism involved in the pathogenesis of hypertension in CKD.

Key words: CKD, pathophysiology, hypertension, Renin angiotensin axis.

How to cite this article: Rashmi SR, Vishwanath S. Pathophysiology of Hypertension in Chronic Kidney Disease. Hypertens 2018;4(3):166-169.

Source of support: Nil,

Conflict of interest: None

Received: 01-03-2018;

Accepted: 4-04-2018


How to cite this article: Rashmi SR, Vishwanath S. Pathophysiology of Hypertension in Chronic Kidney Disease. Hypertens 2018;4(3):166-169.

Source of support: Nil,

Conflict of interest: None

11.REVIEW ARTICLE

Hypertension in Post-renal Transplant Patients

Anand R. Shenoy, Saikat Kanjilal

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:170-176] [No. of Hits: 569]


ABSTRACT

Hypertension in renal transplant recipients is known to be a major risk factor for cardiovascular morbidity and mortality, as also reduced allograft survival. Importantly, hypertension in renal transplant patients is common and ranges from 50% to 80% in adult recipients and from 47% to 82% in pediatric recipients. Many patients experience a remarkable improvement in blood pressure (BP) control, requiring lesser medications within months of transplantation. However, the benefits of improved glomerular filtration rate (GFR) and fluid status may be negated by various donor and recipient factors, acute and chronic allograft injury, and immunosuppressive medications, thereby explaining some of the pathophysiologies of post-transplant hypertension. Other contributory factors for hypertension after transplant, beyond a progressive decrease in GFR, include transplant renal artery stenosis and adrenal causes of hypertension, as noted in some patient cohorts. Notably, targets for hypertension management in renal transplant recipients remain an enigma, since there are not sufficient data from randomized controlled trials to support a benefit from targeting lower BP levels on graft and patient survival. Although no specific antihypertensive medications have been shown to be more effective than others at improving survival in this cohort, calcium channel blockers may be the most useful medication for mitigating calcineurin inhibitor-induced vasoconstriction, and their use may improve GFR. Use of inhibitors of the renin-angiotensin system remains an attractive strategy, but the potential for drug-drug interactions and altered pharmacokinetics and pharmacodynamics of the different antihypertensive medications need to be carefully considered. In conclusion, hypertension control affects both patient and long-term transplant survival, thereby necessitating the identification of the underlying pathophysiology and subsequent individualization of treatment goals.

Key words: Hypertension, Renal transplant, Renin angiotensin system

How to cite this article: Shenoy AR, Kanjilal S. Hypertension in Post-renal Transplant Patients. Hypertens 2018;4(3): 170-176.

Source of support: Nil,

Conflict of interest: None

Received: 7-01-2018;

Accepted: 27-03-2018


How to cite this article: Shenoy AR, Kanjilal S. Hypertension in Post-renal Transplant Patients. Hypertens 2018;4(3): 170-176.

Source of support: Nil,

Conflict of interest: None

12.REVIEW ARTICLE

Hypertension and Coronary Artery Disease

Ranjan Shetty, Thabit Ahmed

[Year:2018] [Month:July-September] [Volume:4 ] [Number:3] [Pages No:177-181] [No. of Hits: 534]


ABSTRACT

Hypertension is one of the major modifiable risk factors for atherosclerotic cardiovascular disease, with diastolic blood pressure being the strongest predictor of coronary artery disease. Hypertension is easily detectable and eminently treatable. Existence of J curve is a debatable issue. Effective treatment of blood pressure in hypertensive individuals reduces the risk of atherosclerotic coronary artery disease.

Key words: Hypertension, Coronary artery disease, Risk factor, J curve

How to cite this article: Shetty R, Ahmed T. Hypertension and Coronary Artery Disease. Hypertens 2018;4(3): 177-181.

Source of support: Nil,

Conflict of interest: None

Received: 19-05-2018;

Accepted: 27-05-2018


How to cite this article: Shetty R, Ahmed T. Hypertension and Coronary Artery Disease. Hypertens 2018;4(3): 177-181.

Source of support: Nil,

Conflict of interest: None